All In Biotech

Free tool

FAERS Monitor: Sylvant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125496 or its brand name (Sylvant, Siltuximab). Reports on generic versions are filed under their own applications.

Reports

649

Serious

536

83% of reports

Hospitalization

209

Death reported

137

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use140
  • drug ineffective98
  • cytokine release syndrome60
  • immune effector cell-associated neurotoxicity syndrome47
  • hypertension44
  • disease progression40
  • death37
  • drug effective for unapproved indication33
  • cataract32
  • hepatic steatosis31
  • cushingoid30
  • osteopenia30
  • short stature30
  • product use in unapproved indication27
  • spinal instability25

Reports by year received

View as table
YearReports
20136
20148
201523
201614
20179
201822
201935
202080
202168
202253
202361
2024106
202587
202677

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,510 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
short statureSignal304194.82890.5107,700
spinal instabilitySignal253541.52360.676,618
cushingoidSignal30305.7215.28,729
immune effector cell-associated neurotoxicity syndromeSignal47259.2196.611,742
cytokine release syndromeSignal6097.276.45,607
osteopeniaSignal3064.245.21,801
hepatic steatosisSignal3154.038.31,560
drug effective for unapproved indicationSignal3336.626.21,106
cataractSignal3217.412.4480
disease progressionSignal4011.08.1354
hypertensionSignal446.75.1211
off label useSignal1405.24.5489
product use in unapproved indicationSignal273.52.447
drug ineffectiveSignal982.42.085
death371.41.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.